Pathologic complete response and survival according to germline BRCA1/2 status in triple-negative breast cancer.

Paulina Gebhart¹, Florian Heinzl¹, Chiara Kahl¹, Alev Bari¹, Georg Langs^2,3, Daniela Muhr¹, Christian F Singer¹, Yen Y Tan⁴

¹Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.

²Computational Imaging Research Lab, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.

³Comprehensive Center for Artificial Intelligence in Medicine, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria.

⁴Department of Obstetrics and Gynecology, Comprehensive Cancer Center, Medical University of Vienna, Spitalgasse 23, 1090, Vienna, Austria. yen.tan@meduniwien.ac.at.

PubMed DOI

Abstract

BACKGROUND: Germline BRCA1/2 pathogenic variants (gBRCA-PV) are associated with chemosensitivity in triple-negative breast cancer (TNBC), but whether higher pathologic complete response (pCR) rates translate into improved long-term outcomes remains uncertain. We assessed associations of gBRCA-PV status with pCR, recurrence-free survival (RFS) and breast cancer-specific survival (BCSS) in a real-wo…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.